A 24-Week, Multi-Centre, International, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase III Study With a 78-Week Extension Period to Evaluate the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Alone.

Trial Profile

A 24-Week, Multi-Centre, International, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase III Study With a 78-Week Extension Period to Evaluate the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Alone.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Obesity; Overweight; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Nov 2016 Results of a pooled post-hoc analysis of five phase IIb and 16 phase III studies (including this study) assessing frequency and characteristics of hypersensitivity adverse events, published in the Clinical Drug Investigation.
    • 16 Sep 2016 Results of a pooled analysis from this and 13 other trials, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
    • 16 Sep 2016 Results of a pooled analysis assessing cardiovascular risk factors from 11 phase 3 clinical trials (n=4404) were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top